GlassScriptPhysician profile
Carl Eugene Miller, JR.
NPI 1194991828
$4,444.17
in general payments reported to CMS, 2019-2025
22 companies · $229 in 2025
The $229 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $436 · 2021: $722 · 2022: $376 · 2023: $101 · 2024: $520 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $2,173.29 | 2019-2024 | Augment Injectable |
| Smith+Nephew, INC. | $534.24 | 2019-2024 | Collagenase Santyl |
| Organogenesis INC. | $349.58 | 2020-2025 | Apligraf |
| Depuy Synthes Sales INC. | $222.07 | 2019-2022 | |
| Zyla Life Sciences, INC. | $161.66 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $155.77 | 2019 | |
| Hydrocision, INC. | $127.11 | 2024 | Tenjet |
| Zimmer Biomet Holdings, INC. | $110.26 | 2025 | |
| Tenex Health INC. | $106.97 | 2020 | |
| Integra Lifesciences Corporation | $100.70 | 2023 | Tenoglide |
| Medtronic, INC. | $85.96 | 2024 | Intellis Adaptivestim |
| Paratek Pharmaceuticals, INC. | $68.61 | 2021-2024 | Nuzyra |
| Grt US Holding, INC. | $46.04 | 2020-2021 | |
| Bioventus LLC | $36.15 | 2024-2025 | Exogen Ultrasound Bone Healing System |
| Kowa Pharmaceuticals America, INC. | $28.10 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $27.02 | 2025 | Purified Cortrophin Gel |
| Mimedx Group, INC. | $25.29 | 2025 | |
| Nevro Corp. | $22.94 | 2022 | |
| Polynovo North America LLC | $18.18 | 2024 | Novosorb Btm |
| Vertex Pharmaceuticals Incorporated | $16.53 | 2025 | |
| Averitas Pharma INC. | $14.42 | 2025 | Qutenza |
| Amgen INC. | $13.28 | 2024 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.